827318-97-8

Basic information

• Product Name: Danusertib
• Synonyms: danusertib;N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;PHA-739358;(R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide,PHA739358;Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)- methoxyphenylacetyl)pyrrolo(3,4-C)pyrazol-3-yl)-;Unii-m3X659D0fy;Danusertib(PHA-739358);PHA-739358(Danusertib)
• CAS NO: 827318-97-8
• Molecular Formula: C26H30N6O3
• Molecular Weight: 474.55
• Product Categories: Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Apis;Inhibitor
• Mol File: 827318-97-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 664.149 °C at 760 mmHg
• Flash Point: 355.465 °C
• Appearance: white powder
• Density: 1.322
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.70±0.20(Predicted)
• CAS DataBase Reference: Danusertib(CAS DataBase Reference)
• NIST Chemistry Reference: Danusertib(827318-97-8)
• EPA Substance Registry System: Danusertib(827318-97-8)

Safety Data

• Hazardous Substances Data: 827318-97-8(Hazardous Substances Data)

Usage

Description

Danusertib, also known as PHA-739358, is a potent and selective Aurora kinase inhibitor with potential antineoplastic activity. It is a synthetic small molecule that selectively inhibits the activity of Aurora A and B kinases, which play a crucial role in the regulation of cell cycle progression and are overexpressed in various malignancies. By inhibiting Aurora kinases, Danusertib disrupts the cell cycle, leading to cell cycle arrest, apoptosis, and inhibition of tumor growth.

Uses

Used in Oncology:
Danusertib is used as an antineoplastic agent for the treatment of patients with chronic myeloid leukemia (CML). It has demonstrated efficacy in inducing cell cycle arrest and apoptosis in CML cells, leading to a reduction in tumor burden and improved patient outcomes.
Used in COVID-19 Research:
Danusertib is also a COVID-19-related research product, as it has been identified as a potential therapeutic agent for the treatment of COVID-19. The Aurora kinases have been implicated in the replication and pathogenesis of SARS-CoV-2, the virus responsible for COVID-19. By inhibiting Aurora kinases, Danusertib may help to reduce viral replication and alleviate the severity of the disease in infected patients.

Biological Activity

danusertib (previously known as pha-739358), a 3-aminopyrazole derivative identified during the development of the pyrrolopyrazole sub-series, is a potent small-molecule inhibitor of aurora kinases family members with a dominant inhibition for aurora b kinase (abk). this pan-aurora kinases inhibitor is also able to inhibit several tyrosine kinases, including t315i mutant, ret, trk-a and fibroblast growth factor receptor-1 (fgfr-1), which are involved in multiple malignancies, such as chronic myelogenous leukemia (cml), acute lymphoblastic leukemia (all), thyroid prostate and breast carcinoma. thus, in many previous studies, danusertib exhibits remarkable antitumor activity in a number of different xengorafts, spontaneous, and transgenic animal tumor models with a favorable pharmacokinetic and safety profile.carpinelli p, ceruti r, giorgini ml, cappella p, gianellini l, croci v, degrassi a, texido g, rocchetti m, vianello p, rusconi l, storici p, zugnoni p, arrigoni c, soncini c, alli c, patton v, marsiglio a, ballinari d, pesenti e, fancelli d, moll j. pha-739358, a potent inhibitor of aurora kinases with a selecyive target inhibiton profile relevant to cancer. mol cancer ther 2007; 6(12 pt 1): 3158-3168

InChI:InChI=1/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1